作者:Jlenia Brunetti、Sara Piantini、Marco Fragai、Silvia Scali、Giulia Cipriani、Lorenzo Depau、Alessandro Pini、Chiara Falciani、Stefano Menichetti、Luisa Bracci
DOI:10.3390/molecules25051088
日期:——
selective tumor targeting agents to deliver multiple units of chemotherapy drugs to cancer tissue would improve treatment efficacy and greatly advance progress in cancer therapy. Here we report a new drug delivery system based on a tetrabranched peptide known as NT4, which is a promising cancer theranostic by virtue of its high cancer selectivity. We developed NT4 directly conjugated with one, two, or three
开发选择性肿瘤靶向剂以将多个单位的化疗药物递送至癌组织将提高治疗效果并极大地推进癌症治疗的进展。在这里,我们报告了一种基于称为 NT4 的四分支肽的新药物递送系统,由于其高癌症选择性,它是一种很有前途的癌症治疗诊断学。我们开发了 NT4 与一个、两个或三个单位的紫杉醇和基于 NT4 的纳米系统直接偶联,使用 NIR 发射量子点,加载 NT4 肿瘤靶向剂并与紫杉醇偶联,以获得 NT4-QD-PTX旨在同时检测和杀死肿瘤细胞的纳米装置。当在人结肠腺癌细胞系 HT-29 上测试时,NT4-QD-PTX 的选择性结合和体外细胞毒性高于未标记的 QD-PTX。